Circulating microRNAs in follicular fluid, powerful tools to explore in vitro fertilization process.
Circulating or "extracellular" microRNAs (miRNAs) detected in biological fluids, could be used as potential diagnostic and prognostic biomarkers of several disease, such as cancer, gynecological and pregnancy disorders. However, their contributions in female infertility and in vitro fertilization (IVF) remain unknown. This study investigated the expression profiles of five circulating miRNAs (let-7b, miR-29a, miR-30a, miR-140 and miR-320a) in human follicular fluid from 91 women with normal ovarian reserve and 30 with polycystic ovary syndrome (PCOS) and their ability to predict IVF outcomes. The combination of FF miR-30a, miR-140 and let-7b expression levels discriminated between PCOS and normal ovarian reserve with a specificity of 83.8% and a sensitivity of 70% (area under the ROC curve, AUC = 0.83 [0.73-0.92]; p < 0.0001). FF samples related to low number of mature oocytes (≤2) contained significant less miR-320a levels than those related to a number of mature oocytes >2 (p = 0.04). Moreover, FF let-7b predicted the development of expanded blastocysts with 70% sensitivity and 64.3% specificity (AUC = 0.67 [0.54-0.79]; p = 0.02) and FF miR-29a potential to predict clinical pregnancy outcome reached 0.68 [0.55-0.79] with a sensitivity of 83.3% and a specificity of 53.5% (p = 0.01). Therefore, these miRNAs could provide new helpful biomarkers to facilitate personalized medical care during IVF.
CHU Montpellier, Institute of Regenerative Medicine and Biotherapy, Saint-Eloi Hospital, INSERM U1203, Montpellier, France.|Montpellier 1 University, UFR of Medicine, Montpellier, France.|ART-PGD Department, Arnaud de Villeneuve Hospital, CHU Montpellier, Montpellier, France.
E
E
Scalici
CHU Montpellier, Institute of Regenerative Medicine and Biotherapy, Saint-Eloi Hospital, INSERM U1203, Montpellier, France.
S
S
Traver
CHU Montpellier, Institute of Regenerative Medicine and Biotherapy, Saint-Eloi Hospital, INSERM U1203, Montpellier, France.|Montpellier 1 University, UFR of Medicine, Montpellier, France.
T
T
Mullet
UMR 1049, DIM, CHRU, Montpellier, France.
N
N
Molinari
ART-PGD Department, Arnaud de Villeneuve Hospital, CHU Montpellier, Montpellier, France.
A
A
Ferrières
ART-PGD Department, Arnaud de Villeneuve Hospital, CHU Montpellier, Montpellier, France.
C
C
Brunet
Eylau/Unilabs Laboratory, Reproductive Biology Unit, 55 Rue Saint Didier, 75016 Paris, France.
S
S
Belloc
CHU Montpellier, Institute of Regenerative Medicine and Biotherapy, Saint-Eloi Hospital, INSERM U1203, Montpellier, France.|Montpellier 1 University, UFR of Medicine, Montpellier, France.|ART-PGD Department, Arnaud de Villeneuve Hospital, CHU Montpellier, Montpellier, France.
S
S
Hamamah
D000328:Adult; D000074166:Circulating MicroRNA / Q000032:analysis*; D003955:Diagnostic Tests, Routine / Q000379:methods*; D005260:Female; D005307:Fertilization in Vitro; D015571:Follicular Fluid / Q000737:chemistry*; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000175:diagnosis*; D057285:Precision Medicine / Q000379:methods; D012680:Sensitivity and Specificity; D055815:Young Adult
D000074166:Circulating MicroRNA